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Patients with multiple (5–100) colorectal adenomas (MCRAs) often have no germline mutation in known predisposition genes, but
probably have a genetic origin. We collected a set of 25 MCRA patients with no detectable germline mutation in APC, MYH/MUTYH
or the mismatch repair genes. Extracolonic tumours were absent in these cases. No vertical transmission of the MCRA phenotype
was found. Based on the precedent of MYH-associated polyposis (MAP), we searched for a mutational signature in 241 adenomatous
polyps from our MCRA cases. Somatic mutation frequencies and spectra at APC, K-ras and BRAF were, however, similar to those in
sporadic colorectal adenomas. Our data suggest that the genetic pathway of tumorigenesis in the MCRA patients’ tumours is very
similar to the classical pathway in sporadic adenomas. In sharp contrast to MAP tumours, we did not find evidence of a specific
mutational signature in any individual patient or in the overall set of MCRA cases. These results suggest that hypermutation of APC
does not cause our patients’ disease and strongly suggests that MAP is not a paradigm for the remaining MCRA patients. Our MCRA
patients’ colons showed no evidence of microadenomas, unlike in MAP and familial adenomatous polyposis (FAP). However, nuclear
b-catenin expression was significantly greater in MCRA patients’ tumours than in sporadic adenomas. We suggest that, at least in
some cases, the MCRA phenotype results from germline variation that acts subsequent to tumour initiation, perhaps by causing more
rapid or more likely progression from microadenoma to macroadenoma.
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Individuals who develop multiple colorectal adenomas (MCRAs)
are a genetically and clinically heterogeneous group who are at
increased risk of colorectal cancer (CRC). The MCRA phenotype
can usefully, but arbitrarily, be defined as 5–100 adenomas during
an individual’s lifetime. Germline mutations in the APC gene
account for about 15% of cases with an MCRA phenotype and such
patients are classified as having the dominantly inherited
condition, attenuated FAP (AFAP) (Spirio et al, 1999). An
additional B35% of such patients have biallelic germline
mutations in the MutY-homologue (MUTYH, MYH) gene and
are classified as having the recessive condition MYH-associated
polyposis (MAP) (Sampson et al, 2003; Sieber et al, 2003). MYH
deficiency causes colorectal adenomas through somatic hyper-
mutation of the APC and K-ras genes. The remaining MCRA
patients have no known underlying cause for their phenotype.
MYH was found to be a MCRA predisposition gene because a
striking excess of somatic G:C4T:A transversion was observed
incidentally during an analysis of the APC gene (Al-Tassan et al,
2002). A similar spectrum of K-ras mutations is also found in MAP
patients (Lipton et al, 2003a). In another Mendelian bowel tumour
syndrome, hereditary nonpolyposis colon cancer (HNPCC), the
effects of DNA mismatch repair (MMR) deficiency can be detected
somatically through the presence of microsatellite instability (MSI)
and frameshift mutations in short repeats within genes such as BAX
and TGFBR2 (Woodford-Richens et al, 2001). It follows that, should
some of the remaining MCRA cases be caused by a defect in DNA
repair or by some other form of hypermutation, the somatic mutation
spectrum will reflect the underlying cause of genomic instability.
The primary tumour predisposition in familial adenomatous
polyposis (FAP) and MAP is to colorectal adenomas via APC
mutation. FAP and MAP patients develop not only macroscopic
adenomatous polyps, but also microadenomas (each comprising at
most a few dysplastic crypts) within the large bowel (Lipton et al,
2003a). This is consistent with an increased rate of adenoma
initiation in FAP and MAP. In HNPCC, by contrast, the primary
predisposition is probably to carcinoma (or progression from
adenoma to carcinoma) and microadenomas are generally absent.
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unknown origins might therefore provide clues about the origins
of the disease. A similar line of reasoning can be applied to the
observation that (A)FAP and MAP patients frequently develop
extracolonic adenomas, especially in the duodenum. The similarity
of the MAP and (A)FAP phenotypes suggests that all individuals
predisposed to inactivation of APC may develop both colorectal
and duodenal adenomas. Interestingly, HNPCC patients are at
greatly increased relative risk – but low absolute risk – of small
bowel cancer, but have very few adenomas at this site.
To address the origins of the MCRA phenotype, we have
determined the spectrum of somatic mutations at APC, K-ras and
BRAF in tumours from 25 MCRA patients with no detectable
germline mutation in APC, MYH or the MMR genes. We have
supplemented our molecular analysis with phenotypic data,
microadenoma counts and immunohistochemistry for b-catenin
expression. We have compared our results with data from MAP
and (A)FAP patients. Our results help to classify the remaining
MCRA cases and provide clues to their genetic origins.
MATERIALS AND METHODS
Sample collection and preparation
Twenty-five MCRA patients were recruited through St Mark’s
Hospital Colorectal Cancer Unit and blood was routinely sampled.
Informed consent was obtained before sample collection. Inclusion
criteria for the study were between 10 and 100 synchronous or
metachronous colorectal adenomas, irrespective of follow-up or
(prophylactic) colectomy (see Table 1 for clinical information). A
total of 241 formalin-fixed, paraffin-embedded adenomas were
collected. Germline mutations in APC and MYH had been excluded
by screening all exons and exon–intron boundaries using
fluorescence single-stranded conformational polymorphism (F-
SSCP) analysis or denaturing HPLC analysis (details available from
authors). In addition, multiplex ligation-dependent probe ampli-
fication (MLPA) analysis had been used to screen for germline
deletions or duplications of APC using the Salsa MLPA kit P043
APC (MRC Holland, Amsterdam, The Netherlands) according to
the manufacturer’s instructions. Germline mutations in the MMR
genes MSH2, MLH1 and MSH6 had been excluded previously using
F-SSCP analysis (data not shown). In support of these findings, no
MSI was observed in our patients’ adenomas at the markers used
for loss of heterozygosity (LOH) analysis (see LOH analysis) and
we therefore did not undertake MLPA analysis for the MMR loci.
We also collected 56 formalin-fixed, paraffin-embedded sporadic
adenomas (patients with one or two adenomas and no reported
family history) from 29 individuals. Existing sets of adenomas
from AFAP and MAP patients were largely available for
comparison (Lamlum et al, 2000; Sieber et al, 2003, 2006) although
a small amount of extra data was collected for this study. For all
patients, DNA was extracted from peripheral blood using standard
methods. Tumour and normal tissues were dissected from sections
cut from archival, paraffin-embedded specimens and we estimated
that the resulting tumour DNAs were derived from at least 70%
dysplastic cells. DNA was extracted from these by standard
proteinase K digestion at 551C.
Table 1 Clinical details and summary of somatic APC mutations in MCRA patients
ID Age
Adenoma
no. CRC
Adenomas
analysed
Adenomas
with truncating
mutations Details of truncating mutations (and LOH)
Adenomas with
LOH only
1 75 20 No 11 3 1309 delAAAGA, Q1303X C4T, E1379X G4TN I
2 66 25 No 11 1 1350 delA NI
3 60 25 No 14 1 1310 delAA+LOH 1
4 71 14 No 18 1 Q1303X C4T2
5 61 10 No 4 2 E1379X G4T+LOH, E1379X G4T0
6 51 26 No 2 1 1354 delTT NI
7 52 27 No 9 2 1465 delAG+1461 delAA, 1465 delAG 3
8 65 10 No 4 2 G1312X G4T+LOH, 1573 del 5bp 0
9 61 19 No 6 2 1493 delA, 1493 delA 3
10 73 10 No 4 0 0
11 68 23 Yes (68) 4 0 1
12 69 12 No 7 3 1426 delG, 1446 delT, 1490 insC 0
13 67 27 No 18 0 4
14 73 76 No 3 1 1350 delA NI
15 55 10 No 2 0 0
16 55 17 No 2 1 1259 delAT+1473 delT 0
17 52 50 No 6 2 1411 delT, 1472 delT+LOH 0
18 55 18 No 3 1 1490 insC 0
19 49 15 No 3 0 0
20 66 10 No 3 2 Q1338X C4T+LOH, 1472 insT+LOH 0
21 55 30 No 25 13 1489 insT, 1431 delA, 1489 insC, 1489 insT, 1493 delA,
1472 del55bp,
1488 delTT, 1465 del2bp, 1465 del2bp, 1465
del2bp+LOH,
1465 del2bp,
1465 delG+LOH, 1465 insT
3
22 44 33 No 16 3 1319 delC, 1319 delC, 1466 del2bp 2
23 48 32 No 16 5 1465 delG+LOH, 1491 delT, 1501 delT, 1481 delT,
1500 delA+LOH
1
24 64 50 No 7 2 1465 delAG, 1491 delT 1
25 51 21 No 13 1 1465 delAG+LOH 0
Abbreviations: CRC¼colorectal cancer; LOH¼loss of heterozygosity; MCRA¼multiple colorectal adenoma; NI¼not informative. The table shows: age at diagnosis (years),
total number of adenomas developed to time of study, presence of colorectal carcinoma (and age), number of adenomas analysed in study’ number of adenomas with any
somatic truncating APC mutation found, details of mutations found (codon plus specific base change) including LOH if present and number of adenomas with LOH but no
truncating mutation found (NI at all markers).
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F-SSCP analysis was used to screen formalin-fixed, paraffin-
embedded tumours for somatic APC mutations between codons
1220 and 1620, approximately corresponding to the mutation
cluster region and covering the region between the first 20 amino
acid b-catenin binding/degradation repeat (20AAR) and the first
SAMP repeat. The region was subdivided into 12 amplicons
(details available from authors). Any sample with a bandshift was
sequenced directly in both orientations from a new PCR product.
Exon 1 of K-ras, exon 3 of b-catenin and the mutational hotspot at
codon 600 of BRAF were screened by direct DNA sequencing in
both orientations. Novel mutations were identified through
comparison with the COSMIC database (http://www.sanger.ac.uk/
genetics/CGP/cosmic) and the European APC database (Laurent-
Puig et al, 1998).
LOH analysis
LOH at APC was analysed using microsatellite markers just distal
to the locus (D5S346, D5S421 and D5S656) on the ABI 3100
sequencer. Constitutionally homozygous markers (and occasional
PCR failures) were scored as noninformative. At each marker, LOH
was considered present if the area under one allelic peak in the
adenoma was less than 0.5 times or greater than two times that of
the other allele, after correcting for the relative allelic areas using
constitutional DNA. In the infrequent event of discordance
between markers, precedence was given to the marker closest to
the APC gene.
Immunohistochemistry
Paraffin-embedded sections (4mm) were dewaxed and rehydrated
using a standard xylene method. Endogenous peroxidase was
blocked by incubating the slides in 0.3% hydrogen peroxide (H2O2;
BDH Chemicals Ltd., Poole, Dorset, UK)/phosphate-buffered saline
(PBS) for 30min. The slides were incubated in normal rabbit
serum (NGS–1:25; DAKO Ltd., Ely, Cambridgeshire, UK) for
10min to block nonspecific binding. Primary antibody (b-catenin;
Transduction Labs, BD Biosciences, Oxford, UK) was added to the
slides at 1:100 dilution and incubated for 45min. Positive and
negative control slides were included in every run. The slides were
then washed in PBS and incubated with secondary antibody
(biotinylated rabbit anti-mouse Ig; DAKO Ltd.) for 35min. The
slides were incubated for 30min at room temperature, washed in
PBS and then incubated with streptavidin–peroxidase conjugate
(1:500, P397; DAKO Ltd.) for 35min at room temperature. The
peroxidase activity was demonstrated by activated 3,30-diamino-
benzidinetetrahydrochloride solution (Sigma D5637, Poole, Dorset,
UK) and 0.1% H2O2. The slides were counterstained in Cole’s
haematoxylin (Pioneer Research Chemicals Ltd., Colchester, Essex,
UK), dehydrated and mounted using Pertex mountant (CellPath,
Newton, Powys, UK). Immunohistochemistry was performed on
the multiple adenoma group, sporadic adenomas and, for
comparison, a set of patients with FAP. Slides were then examined
using a conventional light microscope and the level of expression
of b-catenin (1, 2 or 3) was recorded separately for the nucleus,
cytoplasm and cell membrane according to the intensity of
staining in five random high-powered fields per slide. This was
compared directly with staining in normal crypts from each
sample. For membranous expression, in order to normalise results
across different runs of immunohistochemistry, the abnormal
staining for each slide was divided by the membrane staining in
normal cells. Normal cytoplasmic and nuclear expression was so
weak that such a correction was not required. Immunohisto-
chemistry was scored by CT and KH, under the guidance of a
gastrointestinal histopathology specialist (MN); any differences
were resolved by consensus.
RESULTS AND DISCUSSION
Features of the MCRA patients
The clinical features of the 25 MCRA patients are shown in Table 1.
All were of white UK origin. The mean age at presentation was 60
years (median¼61, range¼44–70). Mean polyp number at
presentation was 24 (median¼21, range¼10–76) and the great
majority of polyps were mildly dysplastic tubular or tubulovillous
adenomas less than 5mm in diameter. One patient had CRC at the
time of presentation. No patient had upper gastrointestinal
adenomas and there were no other notable or consistent
extracolonic features. Most MCRA patients were isolated cases,
although a few patients had a single sibling affected with multiple
adenomas. In no case was there multigenerational inheritance of
CRAs. In five patients, CRCs were present in other family
members, although none of these individuals had been reported
as having adenomas.
Our MAP patients presented at a median age of 57 years
(range¼54–69), not significantly different from the MCRA
patients (P¼0.476, Wilcoxon test). The AFAP patients (median
age¼43 years, range¼27–68) were significantly younger than the
MCRA group (P¼0.027, Wilcoxon test). We did not undertake a
comparison of polyp numbers among the patient groups, since this
was determined by our inclusion criteria, but the presence of CRC
at presentation was similarly frequent in all three patient types
(details not shown).
The family histories and phenotypes of our MCRA cases
therefore resembled MAP, except that we found no evidence of a
predisposition to extracolonic disease in the MCRA group. If the
MCRA cases had, like MAP patients, a tendency to hypermutation
of APC in the gastrointestinal tract, we might expect a similar
spectrum of disease to MAP or (A)FAP. Therefore, it is possible
that MCRA results either from hypermutation of APC in the large
bowel only or from a distinct pathogenic mechanism that does not
involve the tendency to inactivate APC.
Somatic mutation and LOH frequencies are similar in
MCRA and sporadic adenomas, but different from AFAP
and MAP
We detected truncating, somatic APC mutations in 49 of 221 (22%)
adenomas from the MCRA group (Table 1). Of 190 informative
tumours, 32 (17%) showed allelic loss (LOH). Two truncating
Table 2 Comparison between APC mutation frequencies in MCRA and other patients
MCRA Sporadic AFAP MAP
Truncating mutation 49/221 (22%) 10/56 (18%)
a 91/242 (38%)
b 25/34 (74%)
c
LOH 32/190 (17%) 5/56 (9%)
d 19/230 (8%)
e 1/34 (3%)
f
Abbreviations: AFAP¼attenuated familial adenomatous polyposis; MAP¼MYH-associated polyposis; MCRA¼multiple colorectal adenoma. Number of adenomas with
mutations out of total successfully analysed (%) are shown, as are numbers of adenomas with LOH at APC out of total informative tumours (%). P values for comparison of
mutation and LOH frequencies with those in the MCRA group using Fisher’s exact test are as follows:
aP¼0.59;
bPo0.001;
cPo0.001;
dP¼0.20;
eP¼0.01;
fP¼0.022. Data were
derived from this study, supplemented by our published work on MAP patients (Lipton et al, 2003a) and AFAP (Sieber et al, 2006).
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tumours had a single APC mutation and LOH. The APC mutation
and LOH frequencies were not significantly different from those
found in the sporadic adenomas (Table 2); however, the AFAP and
MAP tumours had significantly higher frequencies of truncating
mutations and lower frequencies of LOH than the MCRA tumours
(Table 2). No adenoma was found to have a b-catenin mutation.
A total of 12 (12%) K-ras mutations were detected in 97 MCRA
tumours analysed; 10 mutations occurred at codon 12 and two
mutations at codon 13. All of the changes – G12A, G12D, G12V and
G13D – had been reported previously to occur frequently in sporadic
adenomas and CRCs. A little surprisingly, nine out of 85 (11%)
MCRA adenomas analysed had a BRAF mutation (V600E); none of
these adenomas had serrated morphology. No tumour harboured
both K-ras and BRAF mutations. The K-ras and BRAF mutation
frequencies in the MCRA tumours were not significantly different
from those in the sporadic adenomas (five out of 34 (P¼0.47) and
five out of 40 (P¼0.73), respectively; Fisher’s exact test).
The similar frequencies of changes at APC, K-ras and BRAF in
MCRA and sporadic cases suggest that the genetic pathways of
tumorigenesis overlap, at least as regards these three genes. The
differences from MAP and AFAP reinforce the possibility that
hypermutation of APC and/or K-ras does not drive tumorigenesis
in MCRA patients.
No definitive mutational signature in the MCRA patients’
tumours
In the MCRA patients’ tumours, the total of 51 truncating APC
mutations (Table 1) comprised 44 frameshifts (small insertions or
deletions) and seven nonsense mutations (3 C:G4T:A transitions
and four G:C4T:A transversions). Although the proportion of
frameshift mutations was higher than in the APC mutation
database (Laurent-Puig et al, 1998), this probably resulted from
detection bias in small, archival tumours, which were the only
samples available from our patients. We have previously observed
decreased mutation detection sensitivity in such samples (Groves
et al, 2002). In support of this contention, the excess of frameshifts
in the MCRA tumours was very similar (P¼0.44, Fisher’s exact
test) to that in our sporadic adenomas, which had acquired eight
frameshift changes plus one A:T4T:A transition and one
G:C4T:A transversion. The APC mutation spectrum in the MCRA
tumours contrasted with the finding that all 25 truncating
mutations in the MAP tumours were G:C4T:A transversions
(Po0.001, Fisher’s exact test).
We then considered whether there was evidence of a ‘mutational
signature’, especially whether individual patients had a tendency to
frameshift changes, to specific nonsense mutations or to LOH at
APC. In general, no such tendency was evident (Table 1). However,
one patient (no. 21) had acquired frameshift mutations in 13
tumours and no nonsense changes and another (no. 23) had five
frameshift changes and no nonsense changes. These frequencies
were not significantly different from those expected (P40.1, exact
binomial test). It was, however, striking that all changes in the
tumours of patient nos. 21 and 23 occurred in a particular region
of the APC gene, between the second and third 20 amino-acid
repeats that are involved in b-catenin degradation. Such a
spectrum of mutations might be expected in patients with a
germline APC mutation before codon 1280 (Lamlum et al, 1999;
Albuquerque et al, 2002; Crabtree et al, 2003) or with a deficiency
in MMR that did not manifest as MSI in adenomas (Wu et al,
1999). For these reasons, we rescreened patient nos. 21 and 23 for
germline mutations throughout the APC and the MMR genes
MLH1, MSH2, MSH6 and PMS2. We included normal tissue from
around the adenomas in this screen in case the cases were mosaics.
However, no pathogenic changes were found in any of the genes
analysed.
In the MCRA patients, the K-ras mutations comprised six
G:C4A:T, five G:C:4T:A and one G:C4C:G changes. Overall, this
mutation spectrum was similar to that of the sporadic adenomas,
which had nine G:C4A:T, three G:C4T:A and two T:A4A:T
mutations (P¼0.31, Fisher’s exact test). Similar to APC, these
K-ras mutation spectra contrasted with the sole change, G12C
(G:C4T:A), found in MAP tumours. As expected, all of the BRAF
mutations were T:A4A:T transitions resulting in the V600E
change. No adenoma had both K-ras and BRAF mutations. There
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Figure 1 b-Catenin expression in adenoma from MCRA and sporadic patients and FAP cases. The dot plots show (A) the net mean membranous score,
(B) the mean cytoplasmic score and (C) the mean nuclear score from b-catenin immunohistochemistry for MCRA adenomas (series 1), sporadic adenomas
(series 2) and FAP adenomas (series 3). Note that, for ease of depiction, the mean scores from individual adenomas are shown as calculated to one decimal
place, although for statistical analysis, only mean integer values were used. The plots clearly show the lower nuclear expression in sporadic than MCRA and
FAP adenomas. Ideally, a higher mutation pick up rate with less detection bias could be achieved in a larger series of patients resulting in the analysiso fa
higher number of adenomas.
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BRAF mutations (details not shown).
Overall, these findings strongly suggested that there is no
common mutational signature in the MCRA group of patients
subject to the limitations of screening large genes, such as APC in
DNA of relatively poor quantity and quality. Despite these
difficulties, the difference from MAP was striking, once again
suggesting that there is no specific tendency for hypermutation in
our MCRA cases.
No colorectal microadenomas in MCRA cases
Haematoxylin an eosin-stained sections of large bowel from FAP,
AFAP, MAP and multiple adenoma patients were examined by a
histopathology specialist (MN) for the presence of microadenomas
(dysplastic lesions o1mm diameter) in otherwise normal large
bowel mucosa. Microadenomas were present in 16 out of 19 FAP
sections examined, the mean density being 0.22/mm. In AFAP,
microadenomas were present in two out of seven sections
examined from four patients, with mean density of 0.03/mm. In
MAP, microadenomas were present in three out of 16 sections
examined from six patients at 0.01/mm. No microadenomas were
found on examination of 16 sections from seven MCRA patients.
The majority of specimens examined were from colectomies and
therefore sporadic adenoma cases could not be assessed, as it is
very unusual for colectomy to be undertaken in these patients.
Historically, microadenomas have been said to be pathognomic of
FAP, but we have demonstrated that they also occur in AFAP and
MAP. Given that some FAP microadenomas harbour somatic
mutations at APC (Thirlwell, unpublished data), it is possible
that they are the earliest detectable lesion, which has been ‘initiated’
by ‘two hits’ at APC (germline plus somatic mutation for (A)FAP or
two somatic mutations for MAP). The absence of microadenomas in
our patients suggests that their cells does not acquire ‘two hits’ at
APC at an appreciably faster rate than the general population. The
mechanism of tumour predisposition in the MCRA cases may
therefore involve a stage of tumorigenesis that is post-initiation.
b-Catenin expression is increased in MCRA tumours
Relative to the 27 sporadic adenomas, the 57 MCRA tumours showed
increased nuclear b-catenin expression (P¼0.0087, Wilcoxon test)
(Figure 1). There was, however, no significant difference in nuclear
b-catenin expression between the MCRA group’s tumours and a set
of 33 adenomas of similar size from six individuals with FAP
(P¼0.09, Wilcoxon test). Expression was not significantly different
between MCRA and sporadic adenomas in the cytoplasm (P¼0.12,
Wilcoxon test) or at the membrane (P¼0.63, Wilcoxon test)
(Figure 2). Logistic regression analysis incorporating the three sites
of b-catenin expression, adenoma size, degree of dysplasia and
patient age found increased nuclear expression to be the only
significant variable which distinguished MCRA and sporadic
tumours (P¼0.017, OR¼0.22, 95%CI 0.065–0.76).
Unlike the other molecular analyses described above, b-catenin
immunohistochemistry showed clear differences between MCRA
and sporadic adenomas, with expression in MCRA tumours
being similar to FAP. The greater Wnt activation in MCRA
patients’ tumours was too consistent to be readily explained
by the inclusion of one or two individuals with cryptic germline
APC or MYH mutations in the MCRA group. Allowing for the
fact that colorectal microadenomas probably vary in their
progression to macroscopic lesions (Crabtree et al, 2001), this
finding raises the possibility that increased Wnt activation in
MCRA leads microadenomas more rapidly or with greater
probability to progress to macroadenomas. Studies to date (Lipton
et al, 2003b) have not identified germline mutations in Wnt
pathway genes in MCRA cases, but many such genes have not yet
been screened.
CONCLUSION
To date, Mendelian CRC syndromes can be categorised in two
ways. First, the primary predisposition may be to polyps or to
carcinoma. Second, the primary defect may be in either a
‘gatekeeper gene’ (such as APC, LKB1, SMAD4/MADH4 and
ALK3/BMPR1A) or a caretaker/DNA repair gene (such as the
MMR loci and MYH/MUTYH). The set of MCRA patients with no
germline APC or MYH mutations is a priori likely to have a strong
genetic predisposition, given the phenotypic similarity to MAP and
AFAP. In our patients, multigenerational inheritance of multiple
adenomas was not found, suggesting recessive or, perhaps,
multilocus inheritance. Several possible explanations for the
MCRA phenotype exist, and these patients may be a heterogeneous
group. Nevertheless, our results have provided clues as to the
reasons for the MCRA phenotype. We found somatic mutation
frequencies and spectra in MCRA adenomas that were very similar
to comparable sporadic lesions, distinct from AFAP and,
especially, MAP. No microadenomas were found in the MCRA
patients’ colons. These results suggest that hypermutation of APC
does not cause our patients’ disease and strongly suggests that
MAP is not a paradigm for the remaining MCRA patients. Our
preferred model is that those few microadenomas, which do occur
spontaneously in MCRA cases, have an increased chance of
progressing to a macroadenoma. This notion is supported by our
immunohistochemical analysis of b-catenin expression. If this is
the case, it seems unlikely that the predisposition gene is a
‘gatekeeper’ type of tumour suppressor (since MCRA disease
seems to be isolated or recessive) or a ‘caretaker’ (since we have
found no evidence of a specific DNA repair defect). We tentatively
suggest that our data fit best a modified ‘landscaper’ model of
tumorigenesis in which the intra- or extracellular microenviron-
ment of cells is altered to favour tumour progression.
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Figure 2 b-Catenin immunohistochemistry in MCRA patient’s adenoma.
Multiple crypts with nuclear b-catenin expression are shown.
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